ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
April 28, 2014 7:00 AM UTC
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) gained $2.23 to $35.62 last week after partner AbbVie Inc. (NYSE:ABBV) submitted an NDA to FDA for its all-oral regimen comprising ABT-450 plus AbbVie's Norvir ritonavir, ABT-267 and ABT-333 with and without ribavirin to treat HCV genotype 1 infection.
Enanta helped discover ABT-450, an HCV NS3/4A protease inhibitor...